𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A multicenter, prospective study of posttransfusion hepatitis in milan

✍ Scribed by Massimo Colombo; Silvia Oldani; Maria F. Donato; Mauro Borzio; Raffaele Santese; Luigi Roffi; Paolo Viganó; Antonietta Cargnel


Publisher
John Wiley and Sons
Year
1987
Tongue
English
Weight
435 KB
Volume
7
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

✦ Synopsis


We studied the risk of posttransfusion hepatitis in recipients of blood collected from volunteer donors who tested negative for HBsAg and had serum ALT levels less than 1.5 times the upper limit of the normal range. Between October, 1983 and September, 1984, 676 consecutive patients who needed blood or plasma transfusions during or after elective surgery, who had no history of liver disease and had never received blood previously, were studied. The patients were given a total of 4,813 (mean = 7) units. Ninety-six patients developed posttransfusion hepatitis, which yielded a hepatic incidence of 20 cases per 1,000 units of transfused blood. Ninety-two patients had non-A, non-B hepatitis, 3 had hepatitis B and 1 had cytomegalovirus infection. The incubation periods for non-A, non-B hepatitis ranged from 2 to 26 (mean = 9.5 +/- 4) weeks. In 68 (73%) patients, the hepatitis was completely asymptomatic; only 24 (27%) patients developed symptoms, including jaundice and hepatomegaly. There were no cases of fulminant hepatitis. Sixty per cent of the patients still had elevated serum ALT levels 1 year after the onset of hepatitis. The 96 patients with hepatitis had received a mean of 9.6 blood units, as compared to a mean of 6.7 units for the unaffected patients (p less than 0.001). This study demonstrated that non-A, non-B hepatitis remains a common and important complication of blood transfusion despite screening of blood donors for HBsAg and elevated serum ALT levels.


📜 SIMILAR VOLUMES


Hepatitis C virus in a prospective study
✍ Jin-Town Wang; Prof. Teh-Hong Wang; Jaw-Town Lin; Jin-Chuan Sheu; Juei-Low Sung; 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 350 KB 👁 1 views

## Abstract Using an enzyme‐linked immunosorbant assay for antibody against hepatitis C virus (anti‐HCV), serial serum samples from 26 non‐A, non‐B (NANB) posttransfusion hepatitis (PTH) patients were studied in a prospective study in Taiwan. Sixteen (61.5%) of the 26 patients were positive for ant

Atypical manifestations of hepatitis A i
✍ Youn Mu Jung; Sang Jong Park; Jeong Sim Kim; Je-Hyuck Jang; Sang Hyub Lee; Jin-W 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB

## Abstract The clinical outcome of symptomatic hepatitis A and the incidence and clinical characteristics of atypical presentation of hepatitis A were studied using prospective, multicenter design. The atypical presentation included delayed anti‐hepatitis A virus (HAV) immunoglobulin M (IgM) seroc

Field-practice study of sorafenib therap
✍ Massimo Iavarone; Giuseppe Cabibbo; Fabio Piscaglia; Claudio Zavaglia; Antonio G 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 229 KB 👁 2 views

on behalf of the SOFIA (SOraFenib Italian Assessment) study group A multicenter randomized controlled trial established sorafenib as a standard of care for patients with advanced hepatocellular carcinoma (HCC). Because the study was prematurely interrupted due to survival benefits in the sorafenib a

Circulating albumin messenger RNA in hep
✍ V Barbu; A Bonnand; S Hillaire; T Coste; O Chazouilleres; J Gugenheim; E Boucher 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB 👁 2 views

The presence of circulating tumor cells might be an indicator of hematogenous spread of tumor cells leading to extrahepatic metastasis. Messenger RNA (mRNA) expression of human albumin, as a liver specific cell marker, has been proposed for this purpose in hepatocellular carcinoma. We conducted a mu

Hepatitis C virus infection in French he
✍ Salama, Gilles; Rostaing, Lionel; Sandres, Karine; Izopet, Jacques 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 164 KB 👁 2 views

The aims of the study were: (i) to evaluate the prevalence of hepatitis C virus (HCV) antibodies (third generation tests) and RNA (standardized ultrasensitive RT-PCR assay) in a large cohort of hemodialysis patients, and (ii) to correlate HCV markers with bioclinical features and alanineaminotransfe